Age-Related Macular Degeneration and Diabetes-Related Eye Diseases Series ft. Outlook Therapeutics

2023 Community Lecture Series: Age-Related Macular DegenerationПодробнее

Exudative age-related macular degeneration.Подробнее

A new treatment for macular degeneration. #shortsПодробнее

Age-Related Macular Degeneration: Current Treatments and Future TherapiesПодробнее

New and Emerging Treatments for Age-Related Macular Degeneration (AMD)Подробнее

Outlook Therapeutics reaches another milestone with FDA acceptance of wet AMD applicationПодробнее

Diabetic Retinopathy, Age-Related Macular Degeneration, and Access to Eye CareПодробнее

Age-Related Macular Degeneration and Diabetes-Related Eye Diseases Series ft. OcugenПодробнее

Outlook Therapeutics - Russ Trenary, President & CEOПодробнее

"Macular Degeneration: Innovations and Insights" by Dr. Steven Bailey and Dr. Christina FlaxelПодробнее

Age Related Macular DegenerationПодробнее

Outlook Therapeutics submits BLA to FDA for its investigational therapy to treat wet AMDПодробнее

Eyes On 2023: The Evolving World of AMD Diagnosis and TreatmentПодробнее

2024 Community Lecture Series: Age Related Macular DegenerationПодробнее

Lifestyle and Age Related Macular Degeneration (AMD)Подробнее

2022 Community Lecture Series: Age-related Macular DegenerationПодробнее

Diabetes and your eyes: Latest treatments and research.Подробнее

2022 Community Lecture Series: Age-related Macular DegenerationПодробнее